Healthcare investors should strongly consider a long position in Exelixis (EXEL) while the company is beaten down.
Irrational Mr. Market
Oblivious & Overreacting
When the market punished flat fourth-quarter Cabometyx revenues with a 13% drop, it must have overlooked management's discussion in the accompanying earnings call. Management noted that Cabometyx demand in the fourth quarter grew by 5%, explaining the lack of revenue growth as an outcome of a third-quarter inventory buildup.
Those who sold their holdings also failed to consider the label expansion granted by the FDA in December for first-line treatment